STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment

Detection of STRN‐ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis

“…The patient's therapy was subsequently switched to ceritinib and whole brain radiation, which resulted in stable disease for at least 26 months at time of most recent follow up 12 . Finally, a patient with malignant peritoneal mesothelioma showed dramatic response following treatment with ceritinib 13 . These studies highlight the importance of identification of this particular fusion not only for diagnostic purposes, but also for therapeutic benefit.…”

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells

“…1 D) in tumor sample. STRN-ALK translocation is formed by exon 3 of STRN and exon 20 of ALK , retaining the ALK tyrosine kinase domain in the fusion protein, as reported also for other patient cases with the same fusion [ 6 , 7 , 11 ]. Besides the identification of STRN-ALK fusion, the tumor was microsatellite stable and showed no other driver mutations and had a low overall mutation burden.…”

“…Detection of ALK -rearrangements in MPeM suggests that for a small subgroup of patients with this cancer, encompassing particularly pediatric cases, these fusions act as a driver of tumorigenesis making the tumor sensitive to targeted therapy [ 8 , 11 , 23 ]. STRN-ALK fusion was recently reported in another 12-year old MPeM pediatric patient case who had excellent response to second-generation ALK inhibitor ceritinib [11] . Promising ALK inhibitor responses have been reported also in other tumor types with STRN-ALK fusion [ 7 , [24] , [25] – 26 ].…”

“…Here, we report detection of STRN-ALK fusion in a 5-year old pediatric patient diagnosed with widely spread malignant peritoneal mesothelioma (MPeM). Although occurrence of MPeM in young patients is rare, STRN-ALK fusion has been reported before such as in a 12-year old MPeM patient [11] . Hung et al.…”

Precision Therapy for Mesothelioma: Feasibility and New Opportunities

“…ALK positivity was divided into focal weak (no ALK rearrangement) and diffuse strong (ALK rearrangement detected). Sequencing of these samples identified ALK fusion partners STRN, TPM1, ATG16L1 [ 65 ]. This has been translated into clinical practice, where the use of ceritinib in a patient with STRN–ALK-rearranged malignant peritoneal mesothelioma showed response as early as 6 weeks into treatment [ 65 ].…”